Commercially Available GLP- 1 Receptors Agonists for the Management of T2DM Exenatide- Short Acting Agents The first GLP- 1 receptor agonist used in clinical practice was exenatide, which was injected subcutaneously twice a day
Safety signals identified through extended follow-up include: Gastrointestinal effects : Nausea, vomiting, and diarrhea remain the most common adverse events, typically diminishing over time but causing discontinuation in approximately 57% of patients Gallbladder disease : Increased incidence of cholelithiasis and cholecystitis, possibly associated with weight loss, though the exact mechanism remains under investigation Diabetic retinopathy : Risk of complications, particularly with rapid glycemic improvement in patients with pre-existing retinopathy Acute kidney injury : Risk associated with severe gastrointestinal adverse events leading to dehydration Pancreatitis : Rare cases reported, though causality remains uncertain
Ji Y, Li H, Wang F, Gu L
Vitamin B12 + MIC injections can support weight loss and fat metabolism by enhancing the bodys natural ability to break down and utilize stored fat for energy
Best practice is to reconstitute all vials identically (same diluent volume) so injection volume remains constant throughout the protocol
Call Zinnia Health at (855) 430-9439 to find out how to get started